University Surgical Vascular
Watkinsville, Georgia, 30677, United States
Location status: Recruiting
Location contact
David Sailors, MD
CONTACT
David Sailors, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06647017
The objective of this study is to determine if tAN therapy can reduce the volume of blood lost during dialysis AV graft placement procedures.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Watkinsville, Georgia, 30677, United States
Location status: Recruiting
David Sailors, MD
CONTACT
David Sailors, MD
PRINCIPAL_INVESTIGATOR
This study is designed as a randomized, double-blind, sham-controlled, single-center, pilot clinical trial in which adults undergoing dialysis port placement procedures will be randomized 1:1 into one of two treatment groups:
Group 1: Active tAN + standard of care Group 2: Sham tAN + standard of care
Participants will receive 30 minutes of active or sham tAN immediately prior to the dialysis port placement procedure. Blood loss and blood markers will be measured before and during the procedure to measure the effect of the therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Transcutaneous auricular neurostimulation (tAN)
Other names: Sparrow Ascent
Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
Other names: Sparrow Ascent
Time frame: Throughout procedure
Comparison of mean total quantified blood loss in active tAN versus sham tAN groups.
Time frame: First incision to incision closure
Surgery time measured as total time from first incision to incision closure in active tAN versus sham tAN groups.
Time frame: From end of AV graft placement to beginning of surgical site closure
Comparison of mean time to hemostasis in active tAN versus sham tAN groups.
Time frame: During surgery
Proportion of participants requiring hemostatic agents
Time frame: During surgery
Duration of time between completing graft placement and application/administration of hemostatic agent
Time frame: During surgery
Proportion of participants achieving hemostasis in <10 minutes
Time frame: Prior to device placement, during surgery, and at end of surgery
Blood urea nitrogen (BUN) levels, platelet count, hematocrit, and activated clotting time (ACT)
Time frame: Thorough study completion, an average of 4 hours
The proportion of participants who experience one or more treatment-related adverse events.
Contact information is provided by the study sponsor or research team.
University Surgical Vascular
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01731444
Blood Loss, Surgical, Burns
Winnipeg, Manitoba, Canada
View Trial DetailsNCT07721623
Blood Loss, Surgical, Hemorrhage
View Trial DetailsNCT07672158
Blood Loss, Surgical, Brain Damage, Chronic
Melbourne, Victoria, Australia
View Trial DetailsNCT07288697
Blood Loss, Surgical, Degenerative Spine Disease
Istanbul, Turkey (Türkiye)
View Trial Details